Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BMRN stock price vs DGII: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DGII's multiple
Needs DGII P/E.
Implied fair value · at BMRN's multiple
Needs BMRN P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BMRN FY 2025 (ended Dec 31, 2025) · DGII FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 3.75x · EV / EBITDA 21.37x
Capital structure 94% equity / 6% debt · EV / Revenue 6.44x · EV / EBITDA 28.58x
BMRN carries the larger enterprise value at $12.08B against $2.77B; BMRN trades on the lower EV / Revenue multiple (3.75x vs 6.44x); BMRN on the lower EV / EBITDA (21.37x vs 28.58x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BIOMARIN PHARMACEUTICAL INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
DIGI INTERNATIONAL INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.08x
0.25x
Net debt / EBITDA
Leverage against operating earnings
-1.43x
1.42x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$21.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
VERTEX PHARMACEUTICALS INC / MA
BMRN vs VRTX
ALNYLAM PHARMACEUTICALS, INC.
BMRN vs ALNY
Sarepta Therapeutics, Inc.
BMRN vs SRPT
REGENXBIO Inc.
BMRN vs RGNX
IONIS PHARMACEUTICALS INC
BMRN vs IONS
PTC THERAPEUTICS, INC.
BMRN vs PTCT
CISCO SYSTEMS, INC.
BMRN vs CSCO
JUNIPER NETWORKS INC
BMRN vs JNPR
QUALCOMM INC/DE
BMRN vs QCOM
INTEL CORP
BMRN vs INTC
VERISIGN INC/CA
BMRN vs VRSN
Match Group, Inc.
BMRN vs MTCH
$505.32M
$159.15M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
